Politecnico di Torino - Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY

+39 011 090 6100 info@tech-share.it

3-iodothyronamine Synthetic analogues and uses thereof

agingdyslipidemianeurodegenerative diseasesobesitytironamine


The object of the invention is the design synthesis and biological evaluation of new synthetic analogues of 3-iodotironamine (T1AM), an exponent of a class of endogenous molecules deriving from thyroid hormones. The main possible therapeutic uses are: 1) Obesity and dyslipidemy treatment. 2) Neuro-psychiatric and behavioral disorders. 3) neurodegenerative diseases (i.e. Alzheimer’s syndrome)

Technical features

Recent evidences suggest the presence of a strong correlation between obesity and neurodegeneration. Neurodegenerative diseases (NDD) are characterized by a progressive loss of memory and cognition, which eventually can lead to death. This deterioration is mainly due to the inflammation triggered by the deposition of aberrant proteins, oxidative stress and the modification of lipid pathways. These factors are closely related to obesity and overweight, thus correlating high adiposity to a risk factor for metabolic and neurodegenerative diseases. In this context, the reduction of lipids and the effects of memory improvement observed following the administration of these new molecules suggest a new pleiotropic therapeutic approach for the treatment of diseases such as obesity and NDD.

Possible Applications

  • High therapeutic value for treatment of metabolic and neurodegenerative diseases.


  • The newly synthesized molecules are metabolically more stable than endogenous analogs;
  • Molecules are structurally original;
  • The synthesised ccompounds promote autophagic processes.